US Biomarkers Market worth US$34.3 billion by 2029 with 10.8% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., March 31, 2025 /PRNewswire/ -- The global US Biomarkers Market is expected to reach US$34.3 billion by 2029 from US$20.5 billion in 2024, at a CAGR of 10.8% during the forecast period. The growing significance of biomarkers in drug discovery and development, and the growing importance of companion diagnostics are the major driving factors of the US biomarkers market. However, high capital investments and lengthy timelines for biomarker development can hamper market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43
Browse in-depth TOC on "US Biomarkers Market"
150 - Tables
53 – Figures
The consumables segment accounted for the largest share by product & service segment in the US biomarkers market in 2023.
By product & service, the US biomarkers market is categorized into consumables, services, and software. The consumables are further sub-segmented into assay kits, reagents & chemicals, columns & filters. The consumables accounted for the largest share of the US biomarkers market in 2023. The large share of consumables is due to the necessity for high-quality products to ensure accurate test results, coupled with the repetitive need for these consumables due to ongoing sample testing in research and clinical settings. Additionally, the continuous advancements in biomarker research and increasing funding for precision medicine are further driving the demand for consumables.
The safety biomarkers segment accounted for the largest share by type segment in the US biomarker market in 2023.
By type, the US biomarkers market is categorized into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers are sub segmented into predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers, and prognostic biomarkers. The safety biomarkers segment is expected to grow at the highest CAGR during the forecast period. This is due to their importance in ensuring the safety of pharmaceuticals and healthcare interventions. Safety biomarkers are designed to assess the safety profiles, potential adverse effects, and toxicity levels of drugs and treatments during clinical trials and post-marketing surveillance.
The NGS segment is expected to grow at a higher rate during the forecast period.
Based on technology, the US biomarkers market has been segmented into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. The immunoassay technology is sub segmented into ELISA, western blot, and protein microarray. In 2023, the immunoassays segment accounted for the largest share of the biomarkers market, and the NGS segment is expected to grow at a higher growth rate during the forecast period of 2024-2029. The immunoassay segment's growth is driven by its extensive use in clinical settings for diagnosing diseases, monitoring treatment effectiveness, and predicting patient outcomes.
The need for advanced therapies due to the increased prevalence rate of cancer has contributed to the growth of the US biomarkers market.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=43
Key players in the US biomarkers market are Thermo Fisher Scientific Inc. (US), Abbott (US), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), Celerion (US), Standard BioTools (US), BioAgilytix Labs (US), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), and Singulex, Inc. (US).
Study Coverage
The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the US biomarkers market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product/service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the US biomarkers market. Competitive analysis of top players and upcoming startups in the biomarkers market ecosystem is covered in this report.
For more information, Inquire Now!
Related Reports:
Next Generation Sequencing Market
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
SOURCE MarketsandMarkets
Share this article